Literature DB >> 26901841

Anti-Pseudomonas aeruginosa IgY antibodies promote bacterial opsonization and augment the phagocytic activity of polymorphonuclear neutrophils.

Kim Thomsen1, Lars Christophersen1, Peter Østrup Jensen1, Thomas Bjarnsholt1,2, Claus Moser1, Niels Høiby1,2.   

Abstract

Moderation of polymorphonuclear neutrophils (PMNs) as part of a critical defense against invading pathogens may offer a promising therapeutic approach to supplement the antibiotic eradication of Pseudomonas aeruginosa infection in non-chronically infected cystic fibrosis (CF) patients. We have observed that egg yolk antibodies (IgY) harvested from White leghorn chickens that target P. aeruginosa opsonize the pathogen and enhance the PMN-mediated respiratory burst and subsequent bacterial killing in vitro. The effects on PMN phagocytic activity were observed in different Pseudomonas aeruginosa strains, including clinical isolates from non-chronically infected CF patients. Thus, oral prophylaxis with anti-Pseudomonas aeruginosa IgY may boost the innate immunity against Pseudomonas aeruginosa in the CF setting by facilitating a rapid and prompt bacterial clearance by PMNs.

Entities:  

Keywords:  IgY; cystic fibrosis; phagocytosis; pseudomonas aeruginosa

Mesh:

Substances:

Year:  2016        PMID: 26901841      PMCID: PMC4964812          DOI: 10.1080/21645515.2016.1145848

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  45 in total

1.  Retention of specific yolk IgY in the human oral cavity.

Authors:  David Carlander; Hans Kollberg; Anders Larsson
Journal:  BioDrugs       Date:  2002       Impact factor: 5.807

2.  Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.

Authors:  Nicole Mayer-Hamblett; Richard A Kronmal; Ronald L Gibson; Margaret Rosenfeld; George Retsch-Bogart; Miriam M Treggiari; Jane L Burns; Umer Khan; Bonnie W Ramsey
Journal:  Pediatr Pulmonol       Date:  2011-08-09

3.  Antibody production and transfer to egg yolk in chickens.

Authors:  R PATTERSON; J S YOUNGNER; W O WEIGLE; F J DIXON
Journal:  J Immunol       Date:  1962-08       Impact factor: 5.422

Review 4.  Pathogenesis of cystic fibrosis.

Authors:  C Koch; N Høiby
Journal:  Lancet       Date:  1993-04-24       Impact factor: 79.321

5.  Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients.

Authors:  G Taccetti; S Campana; F Festini; M Mascherini; G Döring
Journal:  Eur Respir J       Date:  2005-09       Impact factor: 16.671

Review 6.  Antibiotic allergy in cystic fibrosis.

Authors:  J S Parmar; S Nasser
Journal:  Thorax       Date:  2005-06       Impact factor: 9.139

7.  Attenuation of host defense function of lung phagocytes in young cystic fibrosis patients.

Authors:  Neil E Alexis; Marianne S Muhlebach; David B Peden; Terry L Noah
Journal:  J Cyst Fibros       Date:  2005-12-13       Impact factor: 5.482

8.  Emergence of antibiotic resistance amongst Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Authors:  J W Mouton; J G den Hollander; A M Horrevorts
Journal:  J Antimicrob Chemother       Date:  1993-06       Impact factor: 5.790

9.  Phagocytosis mediated by three distinct Fc gamma receptor classes on human leukocytes.

Authors:  C L Anderson; L Shen; D M Eicher; M D Wewers; J K Gill
Journal:  J Exp Med       Date:  1990-04-01       Impact factor: 14.307

Review 10.  IgY: a promising antibody for use in immunodiagnostic and in immunotherapy.

Authors:  Wilmar Dias da Silva; Denise V Tambourgi
Journal:  Vet Immunol Immunopathol       Date:  2010-01-07       Impact factor: 2.046

View more
  9 in total

1.  Immunotherapy with IgY Antibodies toward Outer Membrane Protein F Protects Burned Mice against Pseudomonas aeruginosa Infection.

Authors:  Fatemeh Norouzi; Bahador Behrouz; Mahya Ranjbar; Seyed Latif Mousavi Gargari
Journal:  J Immunol Res       Date:  2020-05-29       Impact factor: 4.818

2.  Anti-lipopolysaccharide egg yolk antibodies enhance the phagocytosis of mammalian phagocytes.

Authors:  Xin Zhou; Siyuan Ma
Journal:  Biol Open       Date:  2018-06-20       Impact factor: 2.422

Review 3.  IgY antibodies for the immunoprophylaxis and therapy of respiratory infections.

Authors:  Aymn Talat Abbas; Sherif Aly El-Kafrawy; Sayed Sartaj Sohrab; Esam Ibraheem Ahmed Azhar
Journal:  Hum Vaccin Immunother       Date:  2018-09-19       Impact factor: 3.452

Review 4.  Egg yolk antibodies (IgY) and their applications in human and veterinary health: A review.

Authors:  E P V Pereira; M F van Tilburg; E O P T Florean; M I F Guedes
Journal:  Int Immunopharmacol       Date:  2019-05-22       Impact factor: 4.932

5.  Specific egg yolk immunoglobulin as a promising non-antibiotic biotherapeutic product against Acinetobacter baumannii pneumonia infection.

Authors:  Abolfazl Jahangiri; Parviz Owlia; Iraj Rasooli; Jafar Salimian; Ehsan Derakhshanifar; Zahra Aghajani; Sajad Abdollahi; Saeed Khalili; Daryush Talei; Elham Darzi Eslam
Journal:  Sci Rep       Date:  2021-01-21       Impact factor: 4.379

6.  Chicken IgY reduces the risk of Pseudomonas aeruginosa urinary tract infections in a murine model.

Authors:  Franziska A Schwartz; Lars Christophersen; Kim Thomsen; Sarah Baekdal; Maria Pals Bendixen; Mette Jørgensen; Ida Kirstine Bull Rasmussen; Anne Sofie Laulund; Niels Høiby; Claus Moser
Journal:  Front Microbiol       Date:  2022-09-09       Impact factor: 6.064

Review 7.  IgY - turning the page toward passive immunization in COVID-19 infection (Review).

Authors:  Carolina Constantin; Monica Neagu; Teodora Diana Supeanu; Viorica Chiurciu; Demetrios A Spandidos
Journal:  Exp Ther Med       Date:  2020-04-30       Impact factor: 2.447

Review 8.  Immune Responses to Pseudomonas aeruginosa Biofilm Infections.

Authors:  Claus Moser; Peter Østrup Jensen; Kim Thomsen; Mette Kolpen; Morten Rybtke; Anne Sofie Lauland; Hannah Trøstrup; Tim Tolker-Nielsen
Journal:  Front Immunol       Date:  2021-02-22       Impact factor: 7.561

Review 9.  Immunoglobulin Y for Potential Diagnostic and Therapeutic Applications in Infectious Diseases.

Authors:  Lucia Lee; Kate Samardzic; Michael Wallach; Lyn R Frumkin; Daria Mochly-Rosen
Journal:  Front Immunol       Date:  2021-06-09       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.